SCHEMBL3325635

SCHEMBL3325635

Nc1nc(-c2ccccc2)c2cc(C(=O)O)sc2n1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 6/20 0.70
ALDH1A1 P00352 2/20 0.49
KDM4E B2RXH2 1/20 0.49
ADORA2A P29274 4/20 0.47
NUDT1 P36639 1/20 0.47
MAP3K8 P41279 2/20 0.47
PLK4 O00444 1/20 0.45
AURKA O14965 1/20 0.45
DAPK3 O43293 1/20 0.45
CHEK2 O96017 1/20 0.45
CDK1 P06493 1/20 0.45
PIM1 P11309 1/20 0.45
PRKACA P17612 1/20 0.45
CDK2 P24941 1/20 0.45
MAPK9 P45984 1/20 0.45
CSNK1D P48730 1/20 0.45
GSK3A P49840 1/20 0.45
GSK3B P49841 1/20 0.45
RPS6KA3 P51812 1/20 0.45
CSNK2A1 P68400 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetamide SCHEMBL27642801 0.95 HSP90AB1 (0.67) HSP90AB1ALDH1A1KDM4EADORA2ANUDT1
SCHEMBL3321292 0.90 HSP90AB1 (0.68) HSP90AB1ALDH1A1KDM4EADORA2ANUDT1
SCHEMBL13109669 0.84 HSP90AB1 (0.71) HSP90AB1ALDH1A1KDM4EPOLBGAA
SCHEMBL27732019 0.84 HSP90AB1 (0.53) HSP90AB1
SCHEMBL13109664 0.83 HSP90AB1 (0.73) HSP90AB1ALDH1A1KDM4EADORA2APOLB
SCHEMBL3322113 0.82 HSP90AB1 (0.69) HSP90AB1ALDH1A1KDM4EGAACYP1A2
SCHEMBL3321383 0.82 HSP90AB1 (1.00) HSP90AB1CSNK2A1NPC1
SCHEMBL13109668 0.82 HSP90AB1 (0.74) HSP90AB1ALDH1A1KDM4EPOLBGAA
SCHEMBL13109692 0.81 HSP90AB1 (0.78) HSP90AB1ALDH1A1KDM4EPLK4AURKA
SCHEMBL13109687 0.81 HSP90AB1 (0.78) HSP90AB1ADORA2APLK4AURKADAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675861-B1 PYRIMIDOTHIOPHENE COMPOUNDS VERNALIS R&D LTD (GB) 2015-12-23 EP disclosed
EP-1675861-B1 PYRIMIDOTHIOPHENE COMPOUNDS VERNALIS R&D LTD (GB) 2015-12-23 EP disclosed
US-8642594-B2 Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors VERNALIS (R&D) LIMITED (GB) 2014-02-04 US disclosed
US-8642594-B2 Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors VERNALIS (R&D) LIMITED (GB) 2014-02-04 US disclosed
US-8642594-B2 Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors VERNALIS (R&D) LIMITED (GB) 2014-02-04 US disclosed
US-7820658-B2 Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors VERNALIS (CAMBRIDGE) LIMITED (GB) 2010-10-26 US disclosed
US-7820658-B2 Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors VERNALIS (CAMBRIDGE) LIMITED (GB) 2010-10-26 US disclosed
US-7820658-B2 Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors VERNALIS (CAMBRIDGE) LIMITED (GB) 2010-10-26 US disclosed
US-20100120767-A1 Pyrimidothiophene Compounds Barril-Alonso, Xavier (GB) 2010-05-13 US disclosed
US-20100120767-A1 Pyrimidothiophene Compounds Barril-Alonso, Xavier (GB) 2010-05-13 US disclosed
US-20100120767-A1 Pyrimidothiophene Compounds Barril-Alonso, Xavier (GB) 2010-05-13 US disclosed
CN-100455586-C Pyrimidothiophene compounds VERNALIS CAMBRIDGE LTD (GB) 2009-01-28 CN disclosed
US-20070043044-A1 Pyrimidothiophene compounds VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-02-22 US disclosed
US-20070043044-A1 Pyrimidothiophene compounds VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-02-22 US disclosed
US-20070043044-A1 Pyrimidothiophene compounds VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-02-22 US disclosed
CN-1842532-A Pyrimidothiophene compounds VERNALIS CAMBRIDGE LTD (GB) 2006-10-04 CN disclosed
EP-1675861-A1 PYRIMIDOTHIOPHENE COMPOUNDS Vernalis (Cambridge) Limited (GB) 2006-07-05 EP disclosed
WO-2005021552-A1 PYRIMIDOTHIOPHENE COMPOUNDS VERNALIS (CAMBRIDGE) LTD (GB) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120767-A1 Pyrimidothiophene Compounds ALK, HSP90AA1, HSP90AB1 HSP90AB1 3/4885ALDH1A1 83/4885KDM4E 4373/4885
US-20070043044-A1 Pyrimidothiophene compounds ALK, HSP90AA1, HSP90AB1 HSP90AB1 3/4885ALDH1A1 91/4885KDM4E 4382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.